These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 20500232)

  • 21. Uridine supplementation enhances hepatic mitochondrial function in thymidine-analogue treated HIV-infected patients.
    Banasch M; Goetze O; Knyhala K; Potthoff A; Schlottmann R; Kwiatek MA; Bulut K; Schmitz F; Schmidt WE; Brockmeyer NH
    AIDS; 2006 Jul; 20(11):1554-6. PubMed ID: 16847412
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antiretroviral induced adverse drug reactions in Iranian human immunodeficiency virus positive patients.
    Khalili H; Dashti-Khavidaki S; Mohraz M; Etghani A; Almasi F
    Pharmacoepidemiol Drug Saf; 2009 Sep; 18(9):848-57. PubMed ID: 19551698
    [TBL] [Abstract][Full Text] [Related]  

  • 23. History of viral suppression on combination antiretroviral therapy as a predictor of virological failure after a treatment change.
    Reekie J; Mocroft A; Ledergerber B; Beniowski M; Clotet B; van Lunzen J; Chiesi A; Pradier C; Machala L; Lundgren JD;
    HIV Med; 2010 Aug; 11(7):469-78. PubMed ID: 20201975
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The influence of HIV infection and antiretroviral therapy on the mitochondrial membrane potential of peripheral mononuclear cells.
    Sternfeld T; Schmid M; Tischleder A; Mudra S; Schlamp A; Kost BP; Gruber R; Youle M; Bogner JR; Goebel FD
    Antivir Ther; 2007; 12(5):769-78. PubMed ID: 17713160
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [In-utero antiretroviral exposure and mitochondrial toxicity in a cohort of uninfected infants born to HIV-1-infected women].
    Fernández Ibieta M; Cano JM; Amador JT; González-Tomé MI; Martín SG; Gómez MN; de José MI; Beceiro J; Iglesias E; Prieto L; Santos MJ; Guardia NM; Roa MA; Regidor J
    An Pediatr (Barc); 2010 Oct; 73(4):180-8. PubMed ID: 20951949
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Utility of a 13C-methacetin breath test in evaluating hepatic injury in rats.
    Shirin H; Aeed H; Shalev T; Sorin V; Stavinski S; Shahmurov M; Ilan Y; Avni Y
    J Gastroenterol Hepatol; 2008 Nov; 23(11):1762-8. PubMed ID: 19120861
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Conservation of first-line antiretroviral treatment regimen where therapeutic options are limited.
    Orrell C; Harling G; Lawn SD; Kaplan R; McNally M; Bekker LG; Wood R
    Antivir Ther; 2007; 12(1):83-8. PubMed ID: 17503751
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mitochondrial toxicity in HIV-infected patients both off and on antiretroviral treatment: a continuum or distinct underlying mechanisms?
    Maagaard A; Kvale D
    J Antimicrob Chemother; 2009 Nov; 64(5):901-9. PubMed ID: 19740910
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Growing importance of liver disease in HIV-infected persons.
    Thomas DL
    Hepatology; 2006 Feb; 43(2 Suppl 1):S221-9. PubMed ID: 16447263
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reversible posterior leukoencephalopathy syndrome in 2 HIV-infected patients receiving antiretroviral therapy.
    Ridolfo AL; Resta F; Milazzo L; Caramma I; Matacena G; Antinori S; Galli M
    Clin Infect Dis; 2008 Jan; 46(2):e19-22. PubMed ID: 18171242
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hepatitis C virus viral recurrence and liver mitochondrial damage after liver transplantation in HIV-HCV co-infected patients.
    Duclos-Vallée JC; Vittecoq D; Teicher E; Feray C; Roque-Afonso AM; Lombès A; Jardel C; Gigou M; Dussaix E; Sebagh M; Guettier C; Azoulay D; Adam R; Ichaï P; Saliba F; Roche B; Castaing D; Bismuth H; Samuel D
    J Hepatol; 2005 Mar; 42(3):341-9. PubMed ID: 15710216
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antiretroviral treatment and age-related comorbidities in a cohort of older HIV-infected patients.
    Orlando G; Meraviglia P; Cordier L; Meroni L; Landonio S; Giorgi R; Fasolo M; Faggion I; Riva A; Zambelli A; Beretta R; Gubertini G; Dedivitiis G; Jacchetti G; Cargnel A
    HIV Med; 2006 Nov; 7(8):549-57. PubMed ID: 17105515
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Incidence and risk factors for chronic elevation of alanine aminotransferase levels in HIV-infected persons without hepatitis b or c virus co-infection.
    Kovari H; Ledergerber B; Battegay M; Rauch A; Hirschel B; Foguena AK; Vernazza P; Bernasconi E; Mueller NJ; Weber R
    Clin Infect Dis; 2010 Feb; 50(4):502-11. PubMed ID: 20085465
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The long-term consequences of antiretroviral therapy: a review.
    Boyd M; Reiss P
    J HIV Ther; 2006 Jun; 11(2):26-35. PubMed ID: 16981593
    [No Abstract]   [Full Text] [Related]  

  • 36. Diagnosis of antiretroviral therapy failure in Malawi: poor performance of clinical and immunological WHO criteria.
    van Oosterhout JJ; Brown L; Weigel R; Kumwenda JJ; Mzinganjira D; Saukila N; Mhango B; Hartung T; Phiri S; Hosseinipour MC
    Trop Med Int Health; 2009 Aug; 14(8):856-61. PubMed ID: 19552661
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of time to undetectable HIV viral load in the first 16 weeks after the start of three and four antiretroviral regimens.
    Manavi K; Scott G
    Int J STD AIDS; 2006 Aug; 17(8):522-4. PubMed ID: 16925897
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A 6-month interruption of antiretroviral therapy improves adipose tissue function in HIV-infected patients: the ANRS EP29 Lipostop Study.
    Kim MJ; Leclercq P; Lanoy E; Cervera P; Antuna-Puente B; Maachi M; Dorofeev E; Slama L; Valantin MA; Costagliola D; Lombes A; Bastard JP; Capeau J
    Antivir Ther; 2007; 12(8):1273-83. PubMed ID: 18240867
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mitochondrial and apoptotic in vitro modelling of differential HIV-1 progression and antiretroviral toxicity.
    Morén C; Bañó M; González-Casacuberta I; Catalán-Garcia M; Guitart-Mampel M; Tobías E; Cardellach F; Pedrol E; Peraire J; Vidal F; Domingo P; Miró Ò; Gatell JM; Martínez E; Garrabou G
    J Antimicrob Chemother; 2015 Aug; 70(8):2330-6. PubMed ID: 25921514
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of a prescription-based measure of antiretroviral therapy adherence to predict viral rebound in HIV-infected individuals with viral suppression.
    Cambiano V; Lampe FC; Rodger AJ; Smith CJ; Geretti AM; Lodwick RK; Holloway J; Johnson M; Phillips AN
    HIV Med; 2010 Mar; 11(3):216-24. PubMed ID: 20002781
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.